PARP inhibitors
Description
Poly (ADP-ribose) polymerases, abbreviated as PARPs, are a group of familiar proteins that play a central role in DNA repair employing the base excision repair (BER) pathway. There about 17 proteins in this family out of which the primary nuclear PARPs are PARP-1, PARP-2, PARP-3, and tankyrases 1 and 2 (PARP-5a and -5b) .The PARP family members are known to engage in a wide range of cellular activities, for example, DNA repair, transcription, cellular signaling, cell cycle regulation and mitosis amongst others. The chief functional units of PARP-1 are an amino terminal DNA binding domain (DBD), a central auto modification domain (AMD), and a carboxyl-terminal catalytic domain (CD). PARP inhibitors are currently undergoing clinical trials as targeted treatment modalities of breast, uterine, colorectal and ovarian cancer. This review summarizes current insights into the mechanism of action of PARP inhibitors, its recent clinical trials, and potential next steps in the evaluation of this promising class of anti-cancer drugs.
Translated Descriptions
Translated Description (Arabic)
بوليميرازات بولي (ADP - ريبوز)، التي يتم اختصارها باسم PARPs، هي مجموعة من البروتينات المألوفة التي تلعب دورًا مركزيًا في إصلاح الحمض النووي باستخدام مسار إصلاح استئصال القاعدة (BER). هناك حوالي 17 بروتينًا في هذه العائلة منها PARPs النووية الأولية هي PARP -1 و PARP -2 و PARP -3 و tankyrases 1 و 2 (PARP -5a و -5b). من المعروف أن أفراد عائلة PARP يشاركون في مجموعة واسعة من الأنشطة الخلوية، على سبيل المثال، إصلاح الحمض النووي، والنسخ، والإشارات الخلوية، وتنظيم دورة الخلية والانقسام المتساوي من بين أمور أخرى. الوحدات الوظيفية الرئيسية لـ PARP -1 هي مجال ربط الحمض النووي للمحطة الأمينية (DBD)، ومجال التعديل التلقائي المركزي (AMD)، والمجال الحفاز لمحطة الكربوكسيل (CD). تخضع مثبطات PARP حاليًا لتجارب سريرية كطرق علاج مستهدفة لسرطان الثدي والرحم والقولون والمستقيم والمبيض. تلخص هذه المراجعة الرؤى الحالية حول آلية عمل مثبطات PARP، وتجاربها السريرية الأخيرة، والخطوات التالية المحتملة في تقييم هذه الفئة الواعدة من الأدوية المضادة للسرطان.Translated Description (English)
Poly (ADP-ribose) polymerases, abbreviated as PARPs, are a group of familiar proteins that play a central role in DNA repair employing the base excision repair (BER) pathway. There are about 17 proteins in this family out of which the primary nuclear PARPs are PARP-1, PARP-2, PARP-3, and tankyrases 1 and 2 (PARP-5a and -5b) .The PARP family members are known to engage in a wide range of cellular activities, for example, DNA repair, transcription, cellular signaling, cell cycle regulation and mitosis among others. The chief functional units of PARP-1 are an amino terminal DNA binding domain (DBD), a central auto modification domain (AMD), and a carboxyl-terminal catalytic domain (CD). PARP inhibitors are currently undergoing clinical trials as targeted treatment modalities of breast, uterine, colorectal and ovarian cancer. This review summarizes current insights into the mechanism of action of PARP inhibitors, its recent clinical trials, and potential next steps in the evaluation of this promising class of anti-cancer drugs.Translated Description (French)
Poly (ADP-ribose) polymerases, abréviation de PARPs, are a group of familiar proteins that play a central role in DNA repair employing the base excision repair (BER) pathway. There about 17 proteins in this family out of which the primary nuclear PARPs are PARP-1, PARP-2, PARP-3, and tankyrases 1 and 2 (PARP-5a and -5b) .The PARP family members are known to engage in a wide range of cellular activities, for example, DNA repair, transcription, cellular signaling, cell cycle regulation and mitosis amongst others. The chief functional units of PARP-1 are an amino terminal DNA binding domain (DBD), a central auto modification domain (AMD), and a carboxyl-terminal catalytic domain (CD). PARP inhibitors are currently undergoing clinical trials as targeted treatment modalities of breast, uterine, colorectal and ovarian cancer. This review summarizes current insights into the mechanism of action of PARP inhibitors, its recent clinical trials, and potential next steps in the evaluation of this promising class of anti-cancer drugs.Translated Description (Spanish)
Poly (ADP-ribose) polymerases, abreviado como PARPs, are a group of familiar proteins that play a central role in DNA repair employing the base excision repair (BER) pathway. There about 17 proteins in this family out of which the primary nuclear PARPs are PARP-1, PARP-2, PARP-3, and tankyrases 1 and 2 (PARP-5a and -5b) .The PARP family members are known to engage in a wide range of cellular activities, for example, DNA repair, transcription, cellular signaling, cell cycle regulation and mitosis amongst others. The chief functional units of PARP-1 are an amino terminal DNA binding domain (DBD), a central auto modification domain (AMD), and a carboxyl-terminal catalytic domain (CD). PARP inhibitors are currently undergoing clinical trials as targeted treatment modalities of breast, uterine, colorectal and ovarian cancer. This review summarizes current insights into the mechanism of action of PARP inhibitors, its recent clinical trials, and potential next steps in the evaluation of this promising class of anticancer drugs.Files
s13053-014-0024-8.pdf
Files
(246.3 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:53cd2ee19a908b8aa73417e2a379eb5c
|
246.3 kB | Preview Download |
Additional details
Additional titles
- Translated title (Arabic)
- مثبطات PARP
- Translated title (English)
- PARP inhibitors
- Translated title (French)
- PARP inhibitors
- Translated title (Spanish)
- Inhibidores PARP
Identifiers
- Other
- https://openalex.org/W3192994539
- DOI
- 10.1186/s13053-014-0024-8
References
- https://openalex.org/W1825629489
- https://openalex.org/W1877440701
- https://openalex.org/W1925527451
- https://openalex.org/W1964787941
- https://openalex.org/W196575356
- https://openalex.org/W1975445106
- https://openalex.org/W1976164429
- https://openalex.org/W1992332625
- https://openalex.org/W1993582972
- https://openalex.org/W2005458257
- https://openalex.org/W2009007206
- https://openalex.org/W2013537373
- https://openalex.org/W2016637704
- https://openalex.org/W2034058449
- https://openalex.org/W2048305487
- https://openalex.org/W2057706543
- https://openalex.org/W2060654492
- https://openalex.org/W2072528578
- https://openalex.org/W2074163000
- https://openalex.org/W2086038769
- https://openalex.org/W2104335176
- https://openalex.org/W2106059513
- https://openalex.org/W2116005493
- https://openalex.org/W2134902059
- https://openalex.org/W2142658272
- https://openalex.org/W2150144069
- https://openalex.org/W2152127384
- https://openalex.org/W2156077962
- https://openalex.org/W2159682317
- https://openalex.org/W2162460329
- https://openalex.org/W2163138275
- https://openalex.org/W2171972386
- https://openalex.org/W2340291575
- https://openalex.org/W2529952554
- https://openalex.org/W4249199995